Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Articles

51061 items
12:00 AM, Apr 13, 2000  |  BC Extra | Politics & Policy

Congress bullish on ag biotech

A congressional report to be released Thursday afternoon concludes that foods derived from biotechnology are safe and that "much of the opposition to agricultural biotechnology is politically motivated, not scientifically based." The report will be...
12:00 AM, Apr 13, 2000  |  BC Extra | Politics & Policy

Public Citizen assails poor phase IV compliance

An analysis of data obtained from the FDA indicates that drug sponsors have a poor record of compliance with commitments to conduct post-marketing studies, according to a study released Thursday by Public Citizen's Health Research...
12:00 AM, Apr 13, 2000  |  BC Extra | Financial News

Follow-on market not so hot

More evidence that the market is cooling was provided by two withdrawn follow-ons and a watered-down deal by gene therapy company AVGN, which raised $26 million through the sale of 1 million shares at $26,...
12:00 AM, Apr 13, 2000  |  BC Extra | Financial News

Thursday market watch

QLT PhotoTherapeutics (QLTI; TSE:QLT) was up $2.75 to $59.625 on Thursday following Wednesday's FDA approval of its Visudyne verteporfin photodynamic therapy to treat wet age-related macular degeneration (see BioCentury Extra, April 12)....
12:00 AM, Apr 13, 2000  |  BC Extra | Company News

Hemispherx withdraws EU marketing application

Hemispherx Biopharma Europe (Antwerp, Belgium), an HEB subsidiary, withdrew and plans to resubmit its European application for marketing approval of its Ampligen nucleic acid antiviral agent to treat chronic fatigue syndrome. The company said the...
12:00 AM, Apr 12, 2000  |  BC Extra | Company News

SkyePharma and Sanofi launch Xatral in Europe

SkyePharma (LSE:SKP; SKYE) and partner Sanofi- Synthelabo (Paris, France) launched Xatral XL, a sustained release once daily formulation of alfuzosin in Denmark, Sweden, the Netherlands and the U.K. Xatral, to treat symptoms of benign prostatic...
12:00 AM, Apr 12, 2000  |  BC Extra | Company News

FDA grants Novartis priority review for Zelmac

NOVN received priority review designation for Zelmac tegaserod to treat multiple symptoms of irritable bowel syndrome....
12:00 AM, Apr 12, 2000  |  BC Extra | Company News

ARC suspends use of HemaSure product

The American Red Cross (ARC) is suspending the use of HMSR's r/LS Red Blood Cell Filtration System pending an investigation of what HMSR said was a small number of non-critical adverse reactions in patients who...
12:00 AM, Apr 12, 2000  |  BC Extra | Financial News

Tularik sells overallotment

TLRK raised an additional $9.9 million through the sale of 281,250 shares at $33.125 of the 375,000-share overallotment. Selling share holders sold the remaining 93,750 shares. On March 22, the company raised $65.9 million in...
12:00 AM, Apr 12, 2000  |  BC Extra | Financial News

Aphton raises $16.2 million

APHT sold a private placement of 491,515 shares at $33. Morgan Stanley Dean Witter and Gruntal & Co. assisted in the placement. The company is developing products using its vaccine-like technology for neutralizing hormones to...

Pages